Compare AMRC & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | NBTX |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2010 | 2018 |
| Metric | AMRC | NBTX |
|---|---|---|
| Price | $26.82 | $35.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $37.88 | $36.00 |
| AVG Volume (30 Days) | ★ 569.5K | 55.9K |
| Earning Date | 05-04-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,769,928,000.00 | N/A |
| Revenue This Year | $10.71 | $58.17 |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 28.76 | N/A |
| 52 Week Low | $14.88 | $4.57 |
| 52 Week High | $44.93 | $57.14 |
| Indicator | AMRC | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 44.58 |
| Support Level | $24.44 | $30.15 |
| Resistance Level | $27.25 | $38.29 |
| Average True Range (ATR) | 1.67 | 2.68 |
| MACD | -0.20 | -0.06 |
| Stochastic Oscillator | 32.62 | 51.59 |
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.